Bladder Cancer

The combination of gemcitabine and docetaxel conferred superior high-grade recurrence-free survival compared with standard therapy among adults with high-risk nonmuscle-invasive bladder cancer, results of a retrospective study showed.

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.

A prospective phase 2 trial that evaluated risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer failed to meet a prespecified threshold of noninferiority, according to study results.

SAN FRANCISCO — Transurethral resection of bladder tumor followed by systemic therapy induced stringently defined clinical complete response among more than 40% of patients with muscle-invasive bladder cancer, according to phase 2 study results.

The FDA has approved a gene therapy treatment for adult patients with high-risk bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, according to a press release.

Bladder cancer disproportionately affects older individuals, with diagnosis occurring at a median age of 73 years.

As a nurse, Brianne “Bree” Duncan, RN, BSN, has always had the goal to help and make a difference in her patients’ lives.

Researchers at New York University, Weill Cornell Medicine and New York Genome Center have developed and tested a two-step approach that uses whole-exome sequencing to find genes and pathways that predict response to immunotherapy.

Patients who received treatment for high-grade nonmuscle-invasive bladder cancer had similar outcomes irrespective of European Association of Urology risk status, results of a retrospective study showed.

The FDA granted fast track designation to several oncology and hematology therapies.